Peer-reviewed veterinary case report
Liposome trifluralin treatment reduces parasite in dogs
By Marques, C et al.·Published in Veterinary journal (London, England : 1997)·2008·Unidade de Leishmanioses and Centro de Malá·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis.
- Species:
- dog
Plain-English summary
Five female Beagle dogs with leishmaniosis, a disease caused by parasites, were treated with a special drug delivery system called liposomal trifluralin. After treatment, the dogs showed improvement in their symptoms, indicating a reduction in the parasite burden. However, the levels of antibodies in their blood did not significantly decrease, suggesting that while the treatment helped, it may not have been fully effective. More research is needed to find the best way to use this treatment for better results.
People also search for: dog leishmaniosis treatment · Beagle dog parasite infection · liposomal trifluralin for dogs
Abstract
Liposomes are used as carriers to deliver drugs and to treat diseases where infection is localised in the mononuclear phagocyte system cells, as is the case of leishmaniosis. Trifluralin is a dinitroaniline with proved anti-Leishmania activity in vitro. The efficacy of liposomal trifluralin (LIP/TFL) was studied in the treatment of experimental canine leishmaniosis through quantification of parasite burden using the limiting dilution assay, follow-up of anti-Leishmania antibodies by indirect fluorescent immunoassay and cytokine expression by Reverse Transcriptase-PCR, in the bone marrow, lymph nodes, skin and peripheral blood mononuclear cells in 5 female beagle dogs. After treatment, dogs showed a general remission of clinical signs related to parasite burden reduction and Th1 cytokine mRNA expression, but there was no significant decrease in antibody levels. Alternative treatment schemes with LIP/TFL are necessary to achieve optimal results.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17855131/